- |||||||||| ORM-6151 / Orum Therap
ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML (Section 15; Poster Board #3) - Mar 14, 2023 - Abstract #AACR2023AACR_4948;
We have previously shown in vitro and in vivo efficacy with a HER2-targeted TPD2 conjugate: ORM-5029...ORM-6151 treatment in CD33-expressing cell lines showed picomolar activity with 10-1000-fold greater potency compared to several GSPT1 degrader molecules, including CC-90009 or Mylotarg, and had robust activity in Mylotarg-resistant lines (AML193 and Kasumi6)...Tumor growth inhibition correlated with the degree and duration of GSPT1 depletion and changes in the expression of previously described integrated stress response biomarker genes. In summary, ORM-6151 is a promising, potential therapy for AML and currently in preclinical development as a first-in-class targeted protein degrader therapy with CD33-targeted delivery.
- |||||||||| ORM-6151 / Orum Therap
ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2152;
The tumor growth inhibition correlated with the degree and duration of GSPT1 depletion and changes in expression of previously described integrated stress response biomarker genes. In summary, ORM-6151 is a promising, potential therapy for AML and currently in preclinical development as a first-in-class targeted protein degrader therapy with CD33-targeted delivery.
|
